Noven Therapeutics, LLC Sustainability Profile
Noven Therapeutics, LLC, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2013, the company has rapidly established itself as a leader in the development of innovative transdermal drug delivery systems, focusing primarily on women's health and hormone replacement therapies. With a commitment to enhancing patient care, Noven Therapeutics offers unique products that leverage advanced technology to improve therapeutic outcomes. Their flagship offerings include a range of transdermal patches that provide consistent and effective medication delivery. Recognised for its dedication to quality and innovation, Noven Therapeutics has achieved significant milestones, positioning itself as a trusted name in the healthcare sector. The company continues to expand its operational reach, contributing to advancements in treatment options for patients across the globe.
DitchCarbon Score
How does Noven Therapeutics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Noven Therapeutics, LLC's score of 30 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Noven Therapeutics, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Hisamitsu Pharmaceutical Co., Inc., which may influence its climate commitments and emissions reporting. As of now, Noven Therapeutics has not established any documented reduction targets or initiatives related to carbon emissions. The absence of specific emissions data and reduction commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given its affiliation with Hisamitsu Pharmaceutical Co., Inc., emissions data and climate initiatives may be cascaded from this parent organisation. However, no specific figures or targets have been provided from this source, indicating a potential gap in transparency regarding Noven's environmental impact. In summary, while Noven Therapeutics, LLC is part of a larger corporate family, it currently lacks detailed emissions data and defined climate commitments, reflecting a broader context within the pharmaceutical industry where many companies are still evolving their sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,986,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,919,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 100,228,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Noven Therapeutics, LLC's Industry?
How Carbon Intensive is Noven Therapeutics, LLC's Location?
Noven Therapeutics, LLC's Scope 3 Categories Breakdown
Noven Therapeutics, LLC's Scope 3 emissions, which decreased by 13% last year and decreased by approximately 11% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 57% of Scope 3 emissions.
Top Scope 3 Categories
Noven Therapeutics, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Noven Therapeutics, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
